lung cancer
Conditions
Interventions
Case series:Carelizumab 200 mg, D1-14, Q2W
Sponsors
The Affiliated Tumor Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects volunteered to join the study, signed the informed consent, had good compliance and cooperated with the interview; 2. Patients aged >=18 years old to 75 years old on the day of signing informed consent; 3. Patients with advanced / recurrent non-small cell lung cancer diagnosed by histopathology and / or cytology who have received one systematic treatment; 4. Patients with at least one measurable lesion (recist1.1) and a history of treatment with any of the systemic anticancer drugs.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. For the target observation group, the following patients with immune system diseases and lung diseases were excluded: (1) Patients with active autoimmune diseases; (2) Patients with a history of chronic or recurrent autoimmune diseases; (3) Patients with interstitial lung disease or pulmonary fibrosis; (4) Patients with a history of pneumonia treated with glucocorticoids; 3. Patients with a history of gastrointestinal hemorrhage or with a clear tendency of gastrointestinal bleeding in the past 6 months, such as esophageal varices with bleeding risk, local active ulcer lesions, fecal occult blood = + +, can not be included in the group; if fecal occult blood (+), gastroscopy is required; 4. Patients who had abdominal fistula, gastrointestinal perforation or abdominal abscess within 28 days before participating in this study; 5. Patients with abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds) with bleeding tendency or undergoing thrombolytic or anticoagulant therapy; 6. The patients whose urine routine showed urine protein >=+ + + or confirmed 24-hour urine protein quantity > 1.0g; 7. Patients who had received strong CYP3A4 inhibitor treatment within 7 days before the study, or received strong CYP3A4 inducer treatment within 12 days before participating in the study; 8. According to the judgment of the researcher, there are accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactRuiling Ning
The Affiliated Tumor Hospital of Guangxi Medical University
Outcome results
None listed